Recent advances in metabolomics in oncology

Bioanalysis

Volumn 4, Issue 4, 2012, Pages 431-451

  O'Connell, Thomas M ^a  

^a LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; GLUTAMIC ACID; TAURINE; TUMOR MARKER;

BLOOD ANALYSIS; BREAST CANCER; CANCER GRADING; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE MAPPING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; MASS FRAGMENTOGRAPHY; MATHEMATICAL MODEL; METABOLOME; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DATA MINING; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MEDICAL ONCOLOGY; METABOLOME; METABOLOMICS; MICE; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC NEOPLASMS; ROC CURVE; SUPPORT VECTOR MACHINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84858055067     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.326     Document Type: Review

References (134)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends and multiple primary cancer analyses from the surveillance, epidemiology and end results (SEER) program. Oncologist 12(1), 20-37 (2007).
2. Oliver SG. Functional genomics: lessons from yeast. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357(1417), 17-23 (2002).
3. Rubinstein WS. Hereditary breast cancer: pathobiology, clinical translation and potential for targeted cancer therapeutics. Fam. Cancer 7(1), 83-89 (2008).
4. Souglakos J. Genetic alterations in sporadic and hereditary colorectal cancer: implementations for screening and follow-up. Dig. Dis. 25(1), 9-19 (2007).
5. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66(6), 1191-1308 (1981).
6. Whiley L, Legido-Quigley C. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis 3(10), 1121-1142 (2011).
7. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1(2), 153-161 (2002). General introduction to the field of metabolomics.
8. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 38(9), 1632-1638 (1992).
9. 1H nuclear magnetic resonance spectroscopy. Anal. Biochem. 304(2), 220-230 (2002).
10. Xi Y, de Ropp JS, Viant MR, Woodruff DL, Yu P. Improved identification of metabolites in complex mixtures using HSQC NMR spectroscopy. Anal. Chim. Acta 614(2), 127-133 (2008).
11. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2(11), 2692-2703 (2007).
12. 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal. Chem. 78(7), 2199-2208 (2006).
13. Logan TM, Murali N, Wang G, Jolivent C. Application of a high-resolution superconducting NMR probe in a natural product structure determination. Magn. Res. Chem. 37, 762-765 (1999).
14. Olson DL, Norcross JA, O'Neil-Johnson M et al. Microflow NMR: concepts and capabilities. Anal. Chem. 76(10), 2966-2974 (2004).
15. Want EJ, Cravatt BF, Siuzdak G. The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem 6(11), 1941-1951 (2005). Detailed introduction to the role of MS in metabolomics.
16. Qiu Y, Cai G, Su M et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome Res. 8(10), 4844-4850 (2009).
17. Rychlik M, Asam S. Stable isotope dilution assays in mycotoxin analysis. Anal. Bioanal. Chem. 390(2), 617-628 (2008).
18. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26(1), 51-78 (2007).
19. Pasikanti KK, Ho PC, Chan EC. Gas chromatography-mass spectrometry in metabolic profiling of biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871(2), 202-211 (2008).
20. Bruce SJ, Tavazzi I, Parisod V, Rezzi S, Kochhar S, Guy PA. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography-mass spectrometry. Anal. Chem. 81(9), 3285-3296 (2009).
21. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics: a review in human disease diagnosis. Anal. Chim. Acta 659(1-2), 23-33 (2010). Describes the application of a number of statistical tools used to interrogate metabolomics datasets.
22. Xu CJ, Hoefsloot HC, Smilde AK. To aggregate or not to aggregate high-dimensional classifiers. BMC Bioinformatics 12, 153 (2011).
23. Scott IM, Vermeer CP, Liakata M et al. Enhancement of plant metabolite fingerprinting by machine learning. Plant Physiol. 153(4), 1506-1520 (2010).
24. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19(2), 223-229 (2007).
25. Warburg O, Posener K, Negelein E. Uber den stoffwechsel der tumoren. Biochem. Z 152, 319-344 (1924).
26. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6), 472-482 (2008). Details many of the metabolic pathways affected by cancer.
27. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26(2), 299-310 (2007).
28. Fischer K, Hoffmann P, Voelkl S et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9), 3812-3819 (2007).
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4(11), 891-899 (2004).
30. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
31. Crawford ED. PSA testing: what is the use? Lancet 365(9469), 1447-1449 (2005).
32. Wilson SS, Crawford ED. Screening for prostate cancer. Clin. Prostate Cancer 3(1), 21-25 (2004).
33. 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn. Reson. Med. 29(3), 285-291 (1993).
34. 1H magnetic resonance spectra. Cancer Res. 57(16), 3398-3401 (1997).
35. Maxeiner A, Adkins CB, Zhang Y et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 70(7), 710-717 (2010).
36. Thysell E, Surowiec I, Hornberg E et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 5(12), e14175 (2010).
37. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009). Detailed investigation that proposed sarcosine as a potential prostate cancer biomarker.
38. Rhodes DR, Kalyana-Sundaram S, Tomlins SA et al. Molecular concepts analysis links tumors, pathways, mechanisms and drugs. Neoplasia 9(5), 443-454 (2007).
39. Tomlins SA, Mehra R, Rhodes DR et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39(1), 41-51 (2007).
40. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 14(2), 166-172 (2011).
41. Jentzmik F, Stephan C, Miller K et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58(1), 12-18, discussion 20-21 (2010). Follow-up analysis on sarcosine that points out some of the potential problems in human metabolomics investigations.
42. Lokhov PG, Dashtiev MI, Moshkovskii SA, Archakov AI. Metabolite profiling of blood plasma with prostate cancer. Metabolomics 6(1), 156-163 (2010).
43. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine and myo-inositol levels and changes with disease. Prostate 30(4), 248-255 (1997).
44. Serkova NJ, Gamito EJ, Jones RH et al. The metabolites citrate, myoinositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68(6), 620-628 (2008).
45. American Cancer Society. Breast Cancer Facts and Figures 2009-2010. American Cancer Society Inc., Atlanta, GA, USA (2010).
46. Brewster AM, Hortobagyi GN, Broglio KR et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J. Natl Cancer Inst. 100(16), 1179-1183 (2008).
47. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann. Oncol. 20(9), 1505-1510 (2009).
48. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res. Treat. 114(3), 403-412 (2009).
49. Lumachi F, Ermani M, Brandes AA, Basso S, Basso U, Boccagni P. Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. AntiCancer Res. 21(6A), 4105-4108 (2001).
50. Lumachi F, Basso SMM, Basso U (Eds.). Breast cancer recurrence: role of serum tumor markers CEA and CA 15-13. Springer, The Netherlands (2008).
51. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5(5), 303-324 (1992).
52. Bathen TF, Jensen LR, Sitter B et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade and hormone status. Breast Cancer Res. Treat. 104(2), 181-189 (2007).
53. Cheng LL, Chang IW, Smith BL, Gonzalez RG. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J. Magn. Reson. 135(1), 194-202 (1998).
54. Mountford CE, Somorjai RL, Malycha P et al. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br. J. Surg. 88(9), 1234-1240 (2001).
55. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 19(1), 30-40 (2006).
56. Oakman C, Tenori L, Claudino WM et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 22(6), 1295-1301 (2011).
57. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19(4), 980-991 (2001).
58. Asiago VM, Alvarado LZ, Shanaiah N et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 70(21), 8309-8318 (2010).
59. Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal. Chim. Acta 686(1-2), 57-63 (2011).
60. Kim Y, Koo I, Jung BH, Chung BC, Lee D. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 11(Suppl. 2), S4 (2010).
61. Chen Y, Zhang R, Song Y et al. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 134(10), 2003-2011 (2009).
62. de la Fuente A, Bing N, Hoeschele I, Mendes P. Discovery of meaningful associations in genomic data using partial correlation coefficients. Bioinformatics 20(18), 3565-3574 (2004).
63. Henneges C, Bullinger D, Fux R et al. Prediction of breast cancer by profiling of urinary RNA metabolites using support vector machine-based feature selection. BMC Cancer 9, 104 (2009).
64. Schram KH. Urinary nucleosides. Mass Spectrom. Rev. 17(3), 131-251 (1998).
65. Woo HM, Kim KM, Choi MH et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin. Chim. Acta 400(1-2), 63-69 (2009).
66. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 365(9454), 153-165 (2005).
67. Labianca R, Beretta G, Gatta G, de Braud F, Wils J. Colon cancer. Crit. Rev. Oncol. Hematol. 51(2), 145-170 (2004).
68. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat. Rev. Cancer 4(10), 769-780 (2004).
69. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br. Med. Bull. 64, 27-43 (2002).
70. Marshall JR. Prevention of colorectal cancer: diet, chemoprevention and lifestyle. Gastroenterol. Clin. North Am. 37(1), 73-82 (2008).
71. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism and colon cancer: a review of the literature. J. Clin. Gastroenterol. 39(2), 98-109 (2005).
72. 1H magnetic resonance spectroscopy. Metabolomics 5, 292-301 (2009).
73. Chan EC, Koh PK, Mal M et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC-MS). J. Proteome Res. 8(1), 352-361 (2009).
74. Denkert C, Budczies J, Weichert W et al. Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol. Cancer 7, 72 (2008).
75. Ritchie SA, Ahiahonu PW, Jayasinghe D et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 8, 13 (2010).
76. Qiu Y, Cai G, Su M et al. Urinary metabonomic study on colorectal cancer. J. Proteome Res. 9(3), 1627-1634 (2010).
77. Marchesi JR, Holmes E, Khan F et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 6(2), 546-551 (2007).
78. Saric J, Wang Y, Li J et al. Species variation in the fecal metabolome gives insight into differential gastrointestinal function. J. Proteome Res. 7(1), 352-360 (2008).
79. 1H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. NMR Biomed. 21(6), 615-626 (2008).
80. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 22(3), 342-348 (2009).
81. Hassig CA, Tong JK, Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. Chem. Biol. 4(11), 783-789 (1997).
82. Pouillart PR. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci. 63(20), 1739-1760 (1998).
83. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 37(Suppl. 2), S88-S94 (2007).
84. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol. 37(6), 806-813 (2002).
85. Franca AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Br. J. Med. Biol. Res. 37(11), 1689-1705 (2004).
86. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl. 1), S27-S34 (2004).
87. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
88. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
89. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2), 460-468 (2004).
90. Onodera H, Ukai K, Minami Y. Hepatocellular carcinoma cases with five-year survival and prognostic factors affecting the survival time. Tohoku J. Exp. Med. 176(4), 203-211 (1995).
91. Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and a-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 101(3), 513-523 (2006).
92. 1H NMR spectroscopy in conjunction with multivariate data analysis. J. Proteome Res. 6(7), 2605-2614 (2007).
93. 1H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. Tumour Biol. 32(1), 223-231 (2011).
94. Xue R, Lin Z, Deng C et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography-mass spectrometry. Rapid Commun. Mass Spectrom. 22(19), 3061-3068 (2008).
95. Chen T, Xie G, Wang X et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell Proteomics 10(7), M110 004945 (2011).
96. Soga T, Sugimoto M, Honma M et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J. Hepatol. 55(4), 896-905 (2011).
97. Yang J, Xu G, Zheng Y et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813(1-2), 59-65 (2004).
98. Chen J, Wang W, Lv S et al. Metabonomics study of liver cancer based on ultraperformance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal. Chim. Acta 650(1), 3-9 (2009).
99. Echejoh GO, Tanko MN, Manasseh AN, Ogala-Echejoh S, Ugoya SO, Mandong BM. Hepatocellular carcinoma in Jos, Nigeria. Niger. J. Med. 17(2), 210-213 (2008).
100. Ladep NG, Taylor-Robinson SD. Management of liver disease in Nigeria. Clin. Med. 7(5), 439-441 (2007).
101. Shariff MI, Gomaa AI, Cox IJ et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J. Proteome Res. 10(4), 1828-1836 (2011).
102. Shariff MI, Ladep NG, Cox IJ et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J. Proteome Res. 9(2), 1096-1103 (2010).
103. O'Connell TM, Ardeshirpour F, Asher SA et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics 4, 216-225 (2008).
104. Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 25(23), 3151-3157 (2009).
105. Borgan E, Sitter B, Lingjaerde OC et al. Merging transcriptomics and metabolomics: advances in breast cancer profiling. BMC Cancer 10, 628 (2010).
106. Blow B. Biobanking: freezer burn. Nat. Methods 6(2), 173-178 (2009).
107. 1H NMR spectroscopy and multivariate data analysis. Magn. Reson. Med. 66(6), 1531-1540 (2011).
108. Yang Q, Shi X, Wang Y et al. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J. Sep. Sci. 33(10), 1495-1503 (2010).
109. An Z, Chen Y, Zhang R et al. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J. Proteome Res. 9(8), 4071-4081 (2010).
110. Maeda J, Higashiyama M, Imaizumi A et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for nonsmall cell lung cancer: a case control study. BMC Cancer 10, 690 (2010).
111. Rocha CM, Carrola J, Barros AS et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 10(9), 4314-4324 (2011).
112. 1H high-resolution magic angle spinning (HRMAS) NMR spectroscopy. J. Proteome Res. 9(1), 319-332 (2010).
113. Carrola J, Rocha CM, Barros AS et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 10(1), 221-230 (2011).
114. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6(1), 78-95 (2010).
115. Slupsky CM, Steed H, Wells TH et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 16(23), 5835-5841 (2010).
116. Guan W, Zhou M, Hampton CY et al. Ovarian cancer detection from metabolomic liquid chromatography-mass spectrometry data by support vector machines. BMC Bioinformatics 10, 259 (2009).
117. Zhou M, Guan W, Walker LD et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol. Biomarkers Prev. 19(9), 2262-2271 (2010).
118. Chen J, Zhang X, Cao R et al. Serum 27-nor-5β-cholestane-3,7,12,24, 25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J. Proteome Res. 10(5), 2625-2632 (2011).
119. 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J. Proteome Res. 10(4), 1765-1771 (2011).
120. 1H-NMR-based metabonomics. Int. J. Cancer 113(5), 782-788 (2005).
121. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. Omics 15(5), 293-303 (2011).
122. Ganti S, Taylor SL, Kim K et al. Urinary acylcarnitines are altered in human kidney cancer. Int. J. Cancer doi:10.1002/ijc.26274 b (2011) (Epub ahead of print).
123. Kim K, Aronov P, Zakharkin SO et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell Proteomics 8(3), 558-570 (2009).
124. Lin L, Yu Q, Yan X et al. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst 135(11), 2970-2978 (2010).
125. Perroud B, Lee J, Valkova N et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 5, 64 (2006).
126. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 24(5), 613-620 (2010).
127. Zhang H, Wang Y, Gu X, Zhou J, Yan C. Metabolomic profiling of human plasma in pancreatic cancer using pressurized capillary electrochromatography. Electrophoresis 32(3-4), 340-347 (2011).
128. 1H NMR spectroscopy and principal component analysis. Appl. Biochem. Biotechnol. 165(1), 148-154 (2011).
129. Huang Z, Lin L, Gao Y et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell Proteomics 10(10), M111.007922 (2011).
130. Pasikanti KK, Esuvaranathan K, Ho PC et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J. Proteome Res. 9(6), 2988-2995 (2010).
131. Issaq HJ, Nativ O, Waybright T et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography-mass spectrometry. J. Urol. 179(6), 2422-2426 (2008).
132. 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 24(4), 788-797 (2010).
133. Jiye A, Qian S, Wang G et al. Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. PLoS One 5(10), e13186 (2010).
134. American Cancer Society. www.cancer.org